Michele Prisciandaro

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Alice Indini, Lorenza Di Guardo, Carolina Cimminiello et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 193 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Improved Survival +10

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O⁶-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

Federica Morano, Alessandra Raimondi, Filippo Pagani et al. · Journal of Clinical Oncology · 2022 · 120 citations · Full text

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B. Schrock et al. · Annals of Oncology · 2018 · 112 citations · Full text

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study

Filippo Pietrantonio, Giovanni Fucà, Federica Morano et al. · Clinical Cancer Research · 2017 · 107 citations · Full text

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

Filippo Pietrantonio, Alessandra Raimondi, Sara Lonardi et al. · Journal of Clinical Oncology · 2023 · 90 citations

Surgical Oncology, Cancer Management, Immunology +22